



## DAFTAR PUSTAKA

- Alkhaibary, A. et al. (2019) 'Ki-67 labeling index in glioblastoma; does it really matter?', *Hematology/ Oncology and Stem Cell Therapy*. King Faisal Specialist Hospital & Research Centre, 12(2), pp. 82–88. doi: 10.1016/j.hemonc.2018.11.001.
- Altieri, R. et al. (2018) 'Tumor location and patient age predict biological signatures of high-grade gliomas', *Neurosurgical Review*. *Neurosurgical Review*, 41(2), pp. 599–604. doi: 10.1007/s10143-017-0899-8.
- Anshu Gupta, T. D. (2019) 'A Simplified Overview of WHO Classification Update', 8(1), p. 4103. doi: 10.4103/jnrrp.jnrrp.
- Arshad, H., Ahmad, Z., & Hasan, S. H. (2010). Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. *Asian Pacific journal of cancer prevention : APJCP*, 11(6), 1637–1640.
- Bulloch, K., Miller, M. M., Gal-Toth, J., Milner, T. A., Gottfried-Blackmore, A., Waters, E. M., Kaunzner, U. W., Liu, K., Lindquist, R., Nussenzweig, M. C., Steinman, R. M., & McEwen, B. S. (2008). CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. *The Journal of comparative neurology*, 508(5), 687–710. <https://doi.org/10.1002/cne.21668>
- Carroll, D. M. et al. (2019) 'Risk Factors for Childhood and Adult Primary Brain Tumors', pp. 1–31. doi: 10.1093/chemse/bjy049/5059692.
- Cambuzzi, E. (2017) 'The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas O papel das mutações IDH1/2 na patogênese dos glioblastomas secundários', *J Bras Patol Med Lab*, (5), pp. 338–344.
- Chen, J., McKay, R. M. and F, L. (2012) 'Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells', *Cell*, 30(149), pp. 36–47. doi: 10.1016/j.cell.2012.03.009.Chen.
- Chen, R. et al. (2017) 'Glioma Subclassifications and Their Clinical Significance', *Neurotherapeutics*. *Neurotherapeutics*, 14(2), pp. 284–297. doi: 10.1007/s13311-017-0519-x.
- Chen, W. J. et al. (2015) 'Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis', *Asian Pacific Journal of Cancer Prevention*, 16(2), pp. 411–420. doi: 10.7314/APJCP.2015.16.2.411.
- Chiesa-Vottero, A. G., Rybicki, L. A. and Prayson, R. A. (2003) 'Comparison of Proliferation Indices in Glioblastoma Multiforme by Whole Tissue Section vs Tissue Microarray', *American Journal of Clinical Pathology*, 120(6), pp. 902–908. doi: 10.1309/8UAUKFK3NBDMVTNU.
- Cohen, A. L., Holmen, S. L., & Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. *Current neurology and neuroscience reports*, 13(5), 345. <https://doi.org/10.1007/s11910-013-0345-4>
- D'Agostino, P. M., Gottfried-Blackmore, A., Anandasabapathy, N., & Bulloch, K. (2012). Brain dendritic cells: biology and pathology. *Acta neuropathologica*, 124(5), 599–614. <https://doi.org/10.1007/s00401-012-1018-0>
- Esmaeili, M. et al. (2018) 'The direction of tumour growth in glioblastoma patients', *Scientific Reports*, 8(1), pp. 1–6. doi: 10.1038/s41598-018-19420-z.
- Fisher, B. J. et al. (2002) 'Ki-67: A prognostic factor for low-grade glioma?', *International Journal of Radiation Oncology Biology Physics*, 52(4), pp. 996–1001. doi: 10.1016/S0360-3016(01)02720-1.



- Gladson, C. L., Prayson, R. A. and Liu, W. M. (2010) 'The pathobiology of glioma tumors', *Annual Review of Pathology: Mechanisms of Disease*, 5(Cmv), pp. 33–50. doi: 10.1146/annurev-pathol-121808-102109.
- Gritsenko, P. G., Ilina, O. and Friedl, P. (2012) 'Interstitial guidance of cancer invasion', *Journal of Pathology*, 226(2), pp. 185–199. doi: 10.1002/path.3031.
- Hanif, F. et al. (2017) 'Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment', *Asian Pacific Journal of Cancer Prevention*, 18(1), pp. 3–9. doi: 10.22034/APJCP.2017.18.1.3.
- Huang, J. et al. (2019) 'Isocitrate dehydrogenase mutations in glioma: From basic discovery to therapeutics development', *Frontiers in Oncology*, 9(JUN), pp. 1–7. doi: 10.3389/fonc.2019.00506.
- J Strong, M. and Garces, J. (2016) 'Brain Tumors: Epidemiology and Current Trends in Treatment', *Journal of Brain Tumors & Neurooncology*, 01(01), pp. 1–21. doi: 10.4172/2475-3203.1000102.
- Jäkel, S. and Dimou, L. (2017) 'Glial cells and their function in the adult brain: A journey through the history of their ablation', *Frontiers in Cellular Neuroscience*, 11(February), pp. 1–17. doi: 10.3389/fncel.2017.00024.
- Johannessen, A. L. and Torp, S. H. (2006) 'The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas', *Pathology and Oncology Research*, 12(3), pp. 143–147. doi: 10.1007/BF02893360.
- Kaunzner, U. W., Miller, M. M., Gottfried-Blackmore, A., Gal-Toth, J., Felger, J. C., McEwen, B. S., & Bulloch, K. (2012). Accumulation of resident and peripheral dendritic cells in the aging CNS. *Neurobiology of aging*, 33(4), 681–693.e1. <https://doi.org/10.1016/j.neurobiolaging.2010.06.007>
- Kumar, A. and Grivas, A. (2018) 'WHO grade III gliomas: a 3-year institutional retrospective case series analysis of the correlation between IDH-1 mutation, Ki67 and progression free survival (2012-1015)', *Neuro-Oncology*, 20(suppl\_1), pp. i22–i22. doi: 10.1093/neuonc/nox238.098.
- Ladomersky, E. et al. (2019) 'The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma', *Frontiers in Pharmacology*, 10(MAR), pp. 1–13. doi: 10.3389/fphar.2019.00200.
- Larjavaara, S. et al. (2007) 'Incidence of gliomas by anatomic location', *Neuro-Oncology*, 9(3), pp. 319–325. doi: 10.1215/15228517-2007-016.
- Li, L. T. et al. (2015) 'Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review)', *Molecular Medicine Reports*, 11(3), pp. 1566–1572. doi: 10.3892/mmr.2014.2914.
- Li, Q. et al. (2017) 'Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma', *Oncology Letters*, 14(1), pp. 229–233. doi: 10.3892/ol.2017.6123.
- Liang, J. et al. (2020) 'Prognostic factors of patients with Gliomas- A n analysis on 335 patients with Glioblastoma and other forms of Gliomas', *BMC Cancer*. *BMC Cancer*, 20(1), pp. 1–7. doi: 10.1186/s12885-019-6511-6.
- Louis, D. N. et al. (2016) 'The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary', *Acta Neuropathologica*. Springer Berlin Heidelberg, 131(6), pp. 803–820. doi: 10.1007/s00401-016-1545-1.
- Mahase, S. et al. (2017) 'Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas', *American Journal of Pathology*. American Society for Investigative Pathology, 187(5), pp. 940–953. doi: 10.1016/j.ajpath.2017.01.010.



- Maher, E. A. and Bachoo, R. M. (2014) Glioblastoma, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. doi: 10.1016/B978-0-12-410529-4.00078-4.
- Mair, M. J. et al. (2020) 'Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma', *Journal of Neuro-Oncology*. Springer US, 148(1), pp. 187–198. doi: 10.1007/s11060-020-03513-9.
- Matteoni, S. et al. (2020) 'The influence of patient sex on clinical approaches to malignant glioma', *Cancer Letters*, 468, pp. 41–47. doi: <https://doi.org/10.1016/j.canlet.2019.10.012>.
- Mesfin FB, Al-Dhahir MA. Gliomas. [Updated 2020 Jun 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441874/>
- Nelson, J. S., Burchfiel, C. M., Fekedulegn, D., & Andrew, M. E. (2012). Potential risk factors for incident glioblastoma multiforme: the Honolulu Heart Program and Honolulu-Asia Aging Study. *Journal of neuro-oncology*, 109(2), 315–321. <https://doi.org/10.1007/s11060-012-0895-3>
- Neurosurgical Review. *Neurosurgical Review*, 42(3), pp. 603–618. doi: 10.1007/s10143-018-1014-5.
- Oslobanu, A. and Florian, S. I. (2015) 'Anatomic locations in high grade glioma', *Romanian Neurosurgery*, 29(3), pp. 271–277. doi: 10.1515/romneu-2015-0036.
- Ostrom, Q. T., Kinnersley, B., Wrensch, M. R., Eckel-Passow, J. E., Armstrong, G., Rice, T., Chen, Y., Wiencke, J. K., McCoy, L. S., Hansen, H. M., Amos, C. I., Bernstein, J. L., Claus, E. B., Il'yasova, D., Johansen, C., Lachance, D. H., Lai, R. K., Merrell, R. T., Olson, S. H., Sadetzki, S., ... Barnholtz-Sloan, J. S. (2018). Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. *Scientific reports*, 8(1), 7352. <https://doi.org/10.1038/s41598-018-24580-z>
- Peter Collins, V. (2013) 'Gliomas', *Brenner's Encyclopedia of Genetics: Second Edition*, 3, pp. 334–336. doi: 10.1016/B978-0-12-374984-0.00652-5.
- Ostrom, Q. T. et al. (2014) 'The epidemiology of glioma in adults: A state of the science review', *Neuro-Oncology*, 16(7), pp. 896–913. doi: 10.1093/neuonc/nou087.
- Sengupta, S., Chatterjee, U., Banerjee, U., Ghosh, S., Chatterjee, S., & Ghosh, A. K. (2012). A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group. *Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology*, 33(1), 25–31. <https://doi.org/10.4103/0971-5851.96965>
- Shivaprasad, N. et al. (2016) 'Ki-67 immunostaining in astrocytomas: Association with histopathological grade-A South Indian study', *Journal of Neurosciences in Rural Practice*, 7(4), pp. 510–514. doi: 10.4103/0976-3147.188626.
- Skjulsvik, A. J. et al. (2014) 'Ki-67/MIB-1 immunostaining in a cohort of human gliomas', *International Journal of Clinical and Experimental Pathology*, 7(12), pp. 8905–8910.
- Stoyanov, G. S. et al. (2017) 'Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation', *Cureus*, 79(6). doi: 10.7759/cureus.1396.
- Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470003/> doi: 10.15586/codon.glioblastoma.2017.ch8
- Tavares, C. B. et al. (2018) 'Expression of Ki-67 in Low-Grade and High-Grade Astrocytomas', *Jbnc - Jornal Brasileiro De Neurocirurgia*, 27(3), pp. 225–230. doi: 10.22290/jbnc.v27i3.1563.



- Theresia, E. et al. (2020) 'Association between Ki-67 labeling index and histopathological grading of Glioma in Indonesian population', *Asian Pacific Journal of Cancer Prevention*, 21(4), pp. 1063–1068. doi: 10.31557/APJCP.2020.21.4.1063.
- Tu, A. et al. (2018) 'Proliferative index in pediatric pilocytic astrocytoma by region of origin and prediction of clinical behavior', *Pediatric Neurosurgery*, 53(6), pp. 395–400. doi: 10.1159/000490466.
- Turkalp, Z., Karamchandani, J. and Das, S. (2014) 'IDH mutation in glioma: New insights and promises for the future', *JAMA Neurology*, 71(10), pp. 1319–1325. doi: 10.1001/jamaneurol.2014.1205.
- Urbańska, K., Sokołowska, J., Szmidi, M., & Sysa, P. (2014). Glioblastoma multiforme - an overview. *Contemporary oncology (Poznan, Poland)*, 18(5), 307–312. <https://doi.org/10.5114/wo.2014.40559>
- Van Den Bent, M. J. et al. (2017) 'A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics', *Neuro-Oncology*, 19(5), pp. 614–624. doi: 10.1093/neuonc/now277.
- Vigneswaran, K., Neill, S. and Hadjipanayis, C. G. (2015) 'Beyond the World Health Organization grading of infiltrating gliomas: Advances in the molecular genetics of glioma classification', *Annals of Translational Medicine*, 3(7), pp. 1–13. doi: 10.3978/j.issn.2305-5839.2015.03.57.
- Walid, M. (2008) 'Prognostic Factors for Long-Term Survival after Glioblastoma', *The Permanente Journal*, 12(4), pp. 45–48. doi: 10.7812/tpp/08-027.
- Walsh, K. M., Ohgaki, H. and Wrensch, M. R. (2016) 'Epidemiology', *Handbook of Clinical Neurology*, 134, pp. 3–18. doi: 10.1016/B978-0-12-802997-8.00001-3.
- Wang, S. et al. (2019) Glioma targeted delivery systems, *Brain Targeted Drug Delivery System*. Elsevier Ltd. doi: 10.1016/b978-0-12-814001-7.00012-3.
- Weller, M. et al. (2015) 'Glioma', *Nature Reviews Disease Primers*, 1(July). doi: 10.1038/nrdp.2015.17.
- Wesseling, P. and Capper, D. (2018) 'WHO 2016 Classification of gliomas', *Neuropathology and Applied Neurobiology*, 44(2), pp. 139–150. doi: 10.1111/nan.12432.
- Wesseling, P., van den Bent, M. and Perry, A. (2015) 'Oligodendroglioma: pathology, molecular mechanisms and markers', *Acta Neuropathologica*. Springer Berlin Heidelberg, 129(6), pp. 809–827. doi: 10.1007/s00401-015-1424-1.
- Yang, L. et al. (2012) 'Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications', *Experimental Cell Research*. Elsevier, 318(19), pp. 2417–2426. doi: 10.1016/j.yexcr.2012.07.017.
- Yuan, Y. et al. (2013) 'Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control', *Seizure*. BEA Trading Ltd, 22(10), pp. 877–881. doi: 10.1016/j.seizure.2013.08.004.
- Zeng, A. et al. (2015) 'IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma', *Oncotarget*, 6(30), pp. 30232–30238. doi: 10.18632/oncotarget.4920.
- Zhang, J. et al. (2019) 'Correlation between glioma location and preoperative seizures: a systematic review and meta-analysis', *Neurosurgical Review*. Neurosurgical Review, 42(3), pp. 603–618. doi: 10.1007/s10143-018-1014-5.